On January 16, 2023 AIGEN Sciences reported that it signed a research cooperation agreement with Yuhan Corporation to identify the mechanism of action of a new artificial intelligence (AI)-based anticancer drug (Press release, AIGEN Sciences, JAN 16, 2023, View Source [SID1234643564]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This agreement aims to identify the mechanism of action of Yuhan Corporation’s new anticancer drug candidate by applying Igen Science’s proprietary artificial intelligence platform.

Under this contract, Eisen Science predicts the mechanism of action of anticancer drug candidates being developed by Yuhan Corporation by utilizing its own artificial intelligence platform based on transcriptome data that can derive the drug’s potential target and mechanism of action. A target is derived. Yuhan Corporation plans to verify the target and mechanism of action proposed by Eisen Science and then accelerate the follow-up development of a differentiated new anticancer drug.

An official from Eisen Science said, "We are developing innovative new drug candidates through our own and joint development projects using artificial intelligence technology based on cell-level transcriptome data," adding, "Even before the research cooperation agreement with Yuhan Corporation, we were developing domestic anticancer drugs and antibody-drug conjugates. "We have signed contracts with (ADC) development companies and are conducting research to discover candidate substances," he said.